Cocrystal Pharma (Nasdaq:COCP) - Cours de l'action, nouvelles et analyse

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

COCP Aperçu des actions

COCP analyse fondamentale
Score flocon de neige
Évaluation	1/6
Croissance future	0/6
Performances passées	0/6
Santé financière	6/6
Dividendes	0/6

Récompenses

Les revenus ont augmenté 18.5% par an au cours des 5 dernières années

Analyse des risques

Les bénéfices devraient diminuer en moyenne de 15.3% par an au cours des 3 prochaines années

Réalise moins d'un million de dollars de revenus ( $0 )

Actuellement non rentable et ne devrait pas le devenir au cours des 3 prochaines années

N'a pas de capitalisation boursière significative ( $19M )

+ 1 plus de risques

Cocrystal Pharma, Inc. Concurrents

Acasti Pharma

NasdaqCM:ACST

US$24.3m

VYNE Therapeutics

NasdaqCM:VYNE

US$27.7m

Cara Therapeutics

NasdaqCM:CARA

US$18.8m

Talphera

NasdaqGM:TLPH

US$15.3m

Historique des prix et performances

Résumé des plus hauts, des changements et des baisses de prix pour Cocrystal Pharma
Historique des cours de bourse
Prix actuel de l'action	US$1.98
Plus haut sur 52 semaines	US$3.24
Plus bas sur 52 semaines	US$1.33
Bêta	1.41
1Variation sur 1 mois	-12.39%
Variation sur 3 mois	-10.00%
Variation sur 1 an	-30.77%
3Variation sur 3 ans	-85.78%
Variation sur 5 ans	-92.79%
Évolution depuis l'introduction en bourse	-99.19%

Nouvelles et mises à jour récentes

Recent updates

Cocrystal selects its antiviral drug candidate to develop as a treatment for COVID-19

Oct 11

Cocrystal Pharma GAAP EPS of -$0.25 misses by $0.21

Aug 15

Cocrystal Pharma (NASDAQ:COCP) Is In A Good Position To Deliver On Growth Plans

Aug 14

Cocrystal engages Open Orphan to conduct mid-stage trial of oral influenza drug in UK

Aug 08

We're Not Very Worried About Cocrystal Pharma's (NASDAQ:COCP) Cash Burn Rate

Mar 19

Companies Like Cocrystal Pharma (NASDAQ:COCP) Are In A Position To Invest In Growth

Nov 19

We Think Cocrystal Pharma (NASDAQ:COCP) Can Afford To Drive Business Growth

Aug 06

Cocrystal’s soars 11% as CDI-45205 shows excellent antiviral activity against SARS-CoV-2 and variants

Jun 14

We Think Cocrystal Pharma (NASDAQ:COCP) Needs To Drive Business Growth Carefully

May 05

Cocrystal Pharma updates on COVID-19 antiviral development programs

May 03

Investors Who Bought Cocrystal Pharma (NASDAQ:COCP) Shares A Year Ago Are Now Up 94%

Mar 13

Rendement pour les actionnaires

	COCP	US Pharmaceuticals	US Marché
7D	8.8%	2.5%	1.6%
1Y	-30.8%	18.4%	26.4%

Rendement vs Industrie: COCP a sous-performé le secteur US Pharmaceuticals qui a rapporté 16 % au cours de l'année écoulée.

Rendement vs marché: COCP a sous-performé le marché US qui a rapporté 25.6 % au cours de l'année écoulée.

Volatilité des prix

Is COCP's price volatile compared to industry and market?
COCP volatility
COCP Average Weekly Movement	11.0%
Pharmaceuticals Industry Average Movement	10.6%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.1%
10% least volatile stocks in US Market	3.2%

Cours de l'action stable: Le cours de l'action de COCP a été volatil au cours des 3 derniers mois.

Volatilité au fil du temps: La volatilité hebdomadaire de COCP ( 11% ) est restée stable au cours de l'année écoulée, mais reste supérieure à 75 % des actions de US.

À propos de l'entreprise

Fondée	Salariés	PDG	Site web
n/a	12	Sam Lee	www.cocrystalpharma.com

Cocrystal Pharma, Inc. est une société de biotechnologie qui se concentre sur la découverte et le développement de traitements thérapeutiques antiviraux pour les maladies virales graves et/ou chroniques. Elle utilise des technologies basées sur la structure pour créer des médicaments antiviraux destinés principalement à traiter le virus de l'hépatite C (VHC), le virus de la grippe, le coronavirus, le norovirus et les infections virales respiratoires. L'entreprise développe le CC-31244, un inhibiteur non nucléosidique de la polymérase du VHC qui a terminé la phase II d'un essai clinique pour traiter l'infection par le VHC, et le CC-42344, un inhibiteur de PB2 qui a terminé la phase I d'un essai clinique pour traiter l'infection par le virus de la grippe.

Cocrystal Pharma, Inc. Résumé des fondamentaux

Comment les bénéfices et les revenus de Cocrystal Pharma se comparent-ils à sa capitalisation boursière ?
COCP statistiques fondamentales
Capitalisation boursière	US$19.23m
Bénéfices(TTM)	-US$17.93m
Recettes(TTM)	n/a

0.0x

Ratio P/S

-1.1x

Ratio P/E

Le site COCP est-il surévalué ?

Voir Juste valeur et analyse de l'évaluation

Bénéfices et recettes

Principales statistiques de rentabilité tirées du dernier rapport sur les bénéfices (TTM)
COCP compte de résultat (TTM)
Recettes	US$0
Coût des recettes	US$15.72m
Marge brute	-US$15.72m
Autres dépenses	US$2.21m
Les revenus	-US$17.93m

Derniers bénéfices déclarés

Jun 30, 2024

Prochaine date de publication des résultats

s/o

Résultat par action (EPS)	-1.76
Marge brute	0.00%
Marge bénéficiaire nette	0.00%
Ratio dettes/capitaux propres	0%

Quelles ont été les performances à long terme de COCP?

Voir les performances historiques et les comparaisons

COCP Aperçu des actions

Récompenses

Analyse des risques

Cocrystal Pharma, Inc. Concurrents

NasdaqCM:ACST

US$24.3m

NasdaqCM:VYNE

US$27.7m

NasdaqCM:CARA

US$18.8m

NasdaqGM:TLPH

US$15.3m

Historique des prix et performances

Nouvelles et mises à jour récentes

Cocrystal Pharma, Inc. Reports Favorable Results from Single-Ascending Dose Cohorts of Phase 1 Study with CDI-988, its Oral Pan-Viral Norovirus/Coronavirus Protease Inhibitor

Cocrystal Pharma Advances Cc-42344 in Influenza A Phase 2A Study, Expects Topline Results by Late 2024

Cocrystal Pharma, Inc. Announces Completion of Enrollment of 78 Subjects

Cocrystal Pharma, Inc. Provides an Update on the Clinical Development of its Novel, Broad-Spectrum Antiviral Investment Candidates

Cocrystal Pharma, Inc. Announces First-Patient-In for Phase 2A Human Challenge Study Evaluating Oral Cc-42344 in Pandemic and Seasonal Influenza A

Cocrystal Pharma, Inc. Highlights Its Novel Inhaled and Oral Influenza A Antiviral Cc-42344 At the World Vaccine Congress West Coast

Recent updates

Cocrystal Pharma, Inc. Reports Favorable Results from Single-Ascending Dose Cohorts of Phase 1 Study with CDI-988, its Oral Pan-Viral Norovirus/Coronavirus Protease Inhibitor

Cocrystal Pharma Advances Cc-42344 in Influenza A Phase 2A Study, Expects Topline Results by Late 2024

Cocrystal Pharma, Inc. Announces Completion of Enrollment of 78 Subjects

Cocrystal Pharma, Inc. Provides an Update on the Clinical Development of its Novel, Broad-Spectrum Antiviral Investment Candidates

Cocrystal Pharma, Inc. Announces First-Patient-In for Phase 2A Human Challenge Study Evaluating Oral Cc-42344 in Pandemic and Seasonal Influenza A

Cocrystal Pharma, Inc. Highlights Its Novel Inhaled and Oral Influenza A Antiviral Cc-42344 At the World Vaccine Congress West Coast

Cocrystal Pharma, Inc. Doses First Subjects in Clinical Study of CDI-988 for Pandemic Norovirus and Coronavirus

Cocrystal Pharma Reports Highly Favorable Safety and Tolerability Results from a Phase 1 Study with its Oral Antiviral CC-42344 for the Treatment of Pandemic and Seasonal Influenza A

Cocrystal Pharma, Inc. Announces Favorable Safety Data from the Phase 1 Study with Oral Antiviral CC-42344 for the Treatment of Pandemic and Seasonal Influenza A

Cocrystal Pharma, Inc. Announces Enrollment Completed in Phase 1 Influenza A Study with Cocrystal Pharma's Oral Antiviral Candidate Cc-42344

Cocrystal selects its antiviral drug candidate to develop as a treatment for COVID-19

Cocrystal Pharma Announces a 1-for-12 Reverse Stock Split

Consensus forecasts updated

Consensus forecasts updated

Cocrystal Pharma GAAP EPS of -$0.25 misses by $0.21

Cocrystal Pharma (NASDAQ:COCP) Is In A Good Position To Deliver On Growth Plans

Cocrystal Pharma Engages CRO to Conduct Phase 2a Human Challenge Influenza A Clinical Trial with Novel, Broad-Spectrum Antiviral Candidate CC-42344

Cocrystal engages Open Orphan to conduct mid-stage trial of oral influenza drug in UK

Cocrystal Pharma, Inc. Reports CC-42344 Pharmacokinetic Data in Influenza A Once-Daily Dosing

Nasdaq Grants 180 Days to Cocrystal Pharma to Regain Compliance

Price target decreased to US$4.08

Cocrystal Pharma, Inc. Reports Favorable Preliminary Data from Phase 1 Initial Cohorts with Cc-42344, a Novel, Broad-Spectrum Influenza A Antiviral

Cocrystal Pharma, Inc., Annual General Meeting, May 18, 2022

We're Not Very Worried About Cocrystal Pharma's (NASDAQ:COCP) Cash Burn Rate

Price target decreased to US$4.08

Cocrystal Pharma Selects Two Lead Antiviral Drug Candidates for its COVID-19 Oral Drug Program

Cocrystal Pharma Receives FDA Guidance to Advance Clinical Development of its COVID-19 Antiviral CDI-45205

Cocrystal Pharma’s Covid-19 Oral and Intranasal/Pulmonary Protease Inhibitors Exhibit Powerful in Vitro Potency Against the Sars-Cov-2 Omicron Variant

Cocrystal Pharma to Discuss Progress with COVID-19 Antiviral Programs and Clinical Strategy During Noble Capital Markets’ Channelchek Virtual Roadshow

Companies Like Cocrystal Pharma (NASDAQ:COCP) Are In A Position To Invest In Growth

Third quarter 2021 earnings released: US$0.04 loss per share (vs US$0.046 loss in 3Q 2020)

We Think Cocrystal Pharma (NASDAQ:COCP) Can Afford To Drive Business Growth

Cocrystal Pharma, Inc. Completes IND-enabling Studies with CC-42344 for the Treatment of Seasonal and Pandemic Influenza A, Plans to initiate a Phase 1 Trial in the Third Quarter

CocrystalPharma, Inc ’s Lead COVID-19 Antiviral CDI-45205 Shown to be Active Against SARS-CoV-2 and Two Prominent SARS-CoV-2 Variants

Cocrystal’s soars 11% as CDI-45205 shows excellent antiviral activity against SARS-CoV-2 and variants

Co-Founder, Chairman & CEO Gary Wilcox has left the company

Board Member recently sold US$1.7m worth of stock

We Think Cocrystal Pharma (NASDAQ:COCP) Needs To Drive Business Growth Carefully

Cocrystal Pharma, Inc. Provides Update on its COVID-19 Antiviral Discovery and Development Programs

Cocrystal Pharma updates on COVID-19 antiviral development programs

Price target decreased to US$4.50

Full year 2020 earnings released: US$0.17 loss per share (vs US$1.51 loss in FY 2019)

Investors Who Bought Cocrystal Pharma (NASDAQ:COCP) Shares A Year Ago Are Now Up 94%

Cocrystal Pharma, Inc. Extends Drug Discovery Collaboration with HitGen and InterX, Inc

Board Member notifies of intention to sell stock

What Is The Ownership Structure Like For Cocrystal Pharma, Inc. (NASDAQ:COCP)?

Board Member notifies of intention to sell stock

Cocrystal Pharma Provides Summary of Upcoming Presentation at the Reimagine Health Research Symposium

Cocrystal Pharma Announces Further Development of Influenza A/B Antiviral Compounds by Merck Under Exclusive Worldwide License and Collaboration Agreement

New 90-day high: US$2.19

Cocrystal sees 2021 cash burn of $800k a month

Cocrystal Pharma to test CDI-45205 against coronaviruses

Is Cocrystal Pharma (NASDAQ:COCP) In A Good Position To Invest In Growth?

New 90-day high: US$1.71

Third quarter 2020 earnings released: US$0.046 loss per share

New 90-day low: US$0.84

Cocrystal Pharma, Inc. Provides Update on Influenza A Program

United States District Court for the District of New Jersey Enters an Order Preliminarily Approving the Stipulation and Agreement of Settlement with Cocrystal Pharma, Inc

New 90-day low - US$0.93